An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)
Clinical trial NCT06594094 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06594094
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-06
- Primary completion
- 2026-08-02
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.